| (Values in U.S. Thousands) | Jun, 2026 | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -21,100 | -1,220 | -19,230 | -3,020 | -6,580 |
| Net Income Growth | -1,629.51% | +93.66% | -536.76% | +54.10% | -139.27% |
Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. NervGen Pharma Corp. is based in VANCOUVER, British Columbia.
Fiscal Year End Date: 12/31